Cancer Research Blog

Bringing You the Latest in the Search For a Cure

Month: November 2015

A Holistic Approach to Cancer Health Disparities

The following is the fourth in a series of posts from senior NCI scientists and leaders on NCI’s Annual Plan and Budget Proposal for Fiscal Year (FY) 2017, which was submitted to the President on September 17, 2015. The proposal provides an overview of NCI’s priorities and key initiatives and the institute’s funding request for the President to consider in formulating his own FY 2017 budget proposal.

In this fourth post, L. Michelle Bennett, Ph.D., director of the NCI Center for Research Strategy; Worta McCaskill-Stevens, M.D., chief of the NCI Community Oncology and Prevention Trials Research Group; and Sanya Springfield, Ph.D., director of the NCI Center to Reduce Cancer Health Disparities, discuss NCI’s holistic approach to addressing cancer health disparities.

Researcher Interview: Matthew Meyerson

Matthew Meyerson, M.D., Ph.D., Professor of Pathology at Dana-Farber Cancer Institute and Harvard Medical School, Director of the Center for Cancer Genome Discovery at Dana-Farber Cancer Institute, and Institute Member at the Broad Institute, spoke with Amy E Blum for this Researcher Interview. 

Amy E Blum (AB): What is the major focus of your work in cancer genomics? 

FDA Approves Nivolumab for Some Melanomas and Lung Cancers

The Food and Drug Administration (FDA) has expanded the approved uses of the immunotherapy agent nivolumab (Opdivo®).

On September 30, the FDA granted accelerated approval to nivolumab in combination with the antibody ipilimumab (Yervoy®) to treat patients with unresectable or metastatic melanoma that does not have a BRAF V600 mutation. And on October 9, the FDA approved nivolumab for the treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) whose disease has progressed despite treatment with platinum-based chemotherapy.

Antioxidants Accelerate the Growth and Invasiveness of Tumors in Mice

Evidence from two new studies in mice shows that antioxidants—dietary supplements commonly used in the belief that they may help prevent disease—may actually promote tumor growth and metastasis. 

The new findings, authors from both studies said, suggest that cancer patients and people with an increased risk of cancer should avoid taking antioxidant supplements.

NIH-IEEE 2015 Strategic Conference on Healthcare Innovations and Point-of-Care Technologies for Precision Medicine

After nearly a year of effort, NIH and the Institute for Electrical and Electronics Engineering, Engineering in Medicine and Biology Society (IEEE/EMBS) hosted the third iteration of the Healthcare Innovations and Point-of-Care Technologies Conference last week. IEEE is the world’s largest engineering professional association.  Likewise, EMBS is the world’s largest international society of biomedical engineers.

More than 200 experts, across all sectors with a stake in the development and translation of point-of-care technologies in not only high-income countries, but also low- and middle-income countries, came together to share progress and discuss challenges in the field.  A special technical session covering advances in detection, diagnosis, and treatment technologies for cervical cancer was included and featured:

Low Income Is a Barrier to Clinical Trial Enrollment, Study Suggests

In a recent survey study, researchers affiliated with the NCI Community Oncology Research Program (NCORP) found that patients with annual household incomes below $50,000 were less likely to participate in a cancer clinical trial than those with higher incomes. Participation rates were lowest for patients with annual incomes of less than $20,000.

The findings were published October 15 in JAMA Oncology.

Cancer Research Blog © 2016
Frontier Theme